Oklo stock tumbles as Financial Times scrutinizes valuation
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), a medical device company with a market capitalization of $159 million, has secured a partnership with a U.S.-based third-party logistics company to support the commercialization of its FDA-cleared LIBERTY Endovascular Robotic System, according to a company press release. InvestingPro analysis indicates the stock is currently fairly valued based on its proprietary Fair Value model.
The medical device developer plans to begin a limited market release of the LIBERTY System during the fourth quarter of 2025, followed by a broader launch expected in April 2026 at the Society of Interventional Radiology conference.
The unnamed logistics partner specializes in the medical device industry and will provide inventory management from a climate-controlled warehouse strategically positioned near key markets. The arrangement aims to ensure efficient order processing and maintain adequate inventory to meet anticipated demand.
"Having an established logistics provider with deep medtech expertise puts us in a stronger position to achieve our go-to-market initiatives more efficiently," said Michal Ahuvia, Director of Operations at Microbot Medical.
The LIBERTY System is described as a single-use, remotely operated robotic solution for endovascular procedures. Microbot Medical received FDA clearance for the device earlier this year.
The company is establishing commercial infrastructure following regulatory approval as it prepares for the staged product launch. The logistics partnership represents one component of Microbot’s commercialization strategy for its flagship product.
In other recent news, Microbot Medical Inc. has successfully raised approximately $25.2 million through the exercise of preferred investment options. This financial move involved investors purchasing over 12 million shares of common stock, with prices ranging between $1.50 and $2.13 per share. Additionally, the company has issued new series J preferred investment options as part of this transaction. In another development, the Japanese Patent Office granted Microbot Medical its first patent in Japan for its LIBERTY System, a robotic device for surgical tool manipulation. This achievement aligns with the company’s recent FDA 510(k) clearance for the LIBERTY System, marking it as the first single-use, remotely operated robotic system for peripheral endovascular procedures. Following this clearance, H.C. Wainwright raised its price target for Microbot Medical from $9.00 to $12.00, maintaining a Buy rating. The company plans to begin U.S. commercialization of the LIBERTY System in the fourth quarter of 2025. CEO Harel Gadot is also set to present the LIBERTY System at the H.C. Wainwright Annual Investor Conference.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.